Market Currents
DepoMed (DEPO +1.6%) gains after being added to the Focus List at Roth Capital this morning....
-
Thursday, June 21, 2012, 11:14 AM ETDepoMed (DEPO +1.6%) gains after being added to the Focus List at Roth Capital this morning. Roth says the stock's risk/reward is favorable given its present valuation and a number of catalysts including: its update on Gralise's orphan drug status, Janumet XR royalties, Glumetza numbers and Serada news flow.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
